Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

with multiple myeloma. We believe this data supports moving Perifosine into a phase 3 program and we are currently exploring the design of a randomized phase 3 placebo controlled clinical trial."

Two additional clinical posters were presented as follows:

Abstract 3691: Phase 1 Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Thirty of 32 patients enrolled were evaluable for response. Perifosine in combination with Revlimid(R) + dexamethasone achieved a 70% ORR (MR or greater), with 50% of patients achieving at least a partial response (PR). The median progression-free survival (PFS) for the 21 patients (70%) who achieved at least an MR is 10.9 months as of November 2008 (not reached). Twenty-three of the 30 evaluable patients are still alive and the median overall survival has not been reached at 16.8 months. Ten patients remain on active treatment.

Abstract 1010: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom's Macroglobulinemia (WM)

Single agent perifosine achieved a 36% ORR (MR, PR) and 58% stable disease in a heavily pre-treated Waldenstrom's Macroglobulinemia patient population. Clinical benefit was demonstrated as reflected by a median time to progression of 10.7 months.

KRX-0401 (Perifosine) Mechanism of Action and Profile

KRX-0401 (Perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Inferior Vena Cava (IVC) Filters - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is projected to reach US$435 million by 2016. The ... 39% (2015) of the global value while ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... and Washington State are not the ... Oregon , Alaska , and ... November 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are ... tax revenue for state and local governments, in addition to ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... 2012 The U.S. Food and Drug Administration today ... by W.L. Gore and Associates Inc. to include treatment ... aortic transection). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... endovascular graft approved by the FDA to treat a ...
... CHAPEL HILL, N.C., Jan. 13, 2012  Facing patent cliffs ... alliances - either through in-licensing deals or M&A activities ... It,s a sound strategy, but a difficult one to ... and consummating a business is fraught with potential pitfalls. ...
Cached Medicine Technology:FDA Expands Use of Endovascular Graft to Treat Aortic Tears 2Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
(Date:12/19/2014)... The Hermitage Club at Haystack Mountain, ... Valley, announced today that it has unveiled its latest ... , Three time Grammy Award Winner Kenny Loggins kicked ... a trail naming ceremony. Hermitage Club Founder, President Jim ... the theme song for the movie soundtrack to Caddyshack, ...
(Date:12/19/2014)... By Amy Norton ... -- Children born to moms who were exposed to high ... increased risk of developing autism, a U.S. study suggests. ... birth between 1990 and 2002, those exposed to the most ... a baby who later developed autism. And exposure during the ...
(Date:12/19/2014)... Steven Reinberg HealthDay Reporter ... can,t balance on one leg for at least 20 seconds ... suggest. Difficulty standing on one leg may indicate that ... the risk for more serious strokes is high, the investigators ... "Individuals showing instability while standing on one leg, as ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... private practices that have made outstanding and innovative ... support and progression of private practice physical therapy ... Physical Therapy Association. , On behalf of Performance ... owner and CEO of Performance accepted the award ...
(Date:12/17/2014)... December 17, 2014 No matter how ... able to eradicate the head louse parasite—a common childhood ... parents. Each year between six and twelve million individuals ... Miami-based lice removal treatment company comes to the rescue, ... environmentally friendly. With its track record of customer service, ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Researchers say a greater awareness is needed about the risks ... age, they often have // multiple chronic conditions and take ... people as they age. ,Researchers conducted a study to ... at 765 prescriptions , more than 20 percent of the ...
... (TEP), is an incision between the trachea and esophagus ... silicone valve , researchers say this new surgical technique ... patients who have had their voice box and tongue ... operative speech rehabilitation therapy, can provide understandable speech communication ...
... Researchers say nearly one-third of patients don’t get a ... for systolic heart failure, a condition in which the ... to their research they say that those who don’t ... to die within one year than those who do ...
... at detecting cancers in women at high risk of developing ... ,The study involved around 1,900 women with a lifetime breast ... who also carried one of the genes known to put ... the women received a clinical breast exam every six months ...
... people with inhalation anthrax is needed to minimize the ... someone who has anthrax from someone who just has ... question that has remained unanswered. ,That’s the question ... 47 cases of anthrax -- including 11 cases blamed ...
... experience migraine headaches compared with one in 20 adult men. ... same time as menstruation each month. Many women claim they ... new study confirms this happens. ,Researchers analyzed data ... shows that in the five days before menstruation, women were ...
Cached Medicine News:
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
...
Medicine Products: